Interview with Pfenex Explores Market Access and Pricing of Biosimilars in North America
Iselin, NJ, October 19, 2017 --(PR.com)-- SMi Group has announced that Mr Patrick Lucy, CEO of Pfenex, has joined the speaker line-up for the 4th annual Biosimilars North America conference which takes place on November 15 & 16 in New Jersey.
In the run-up to the conference, SMi Group had a quickfire interview with Patrick Lucy. Patrick will be presenting an exclusive session at the conference on where the market for biosimilars is heading, including key milestones and challenges overcome.
Asked about the level of biosimilar discounting is optimal and will we ever see price matching between branded and biosimilar products, Patrick said, "Biosimilars are much more complex, requiring more resources and time to develop than small molecule drugs. In addition, there are far fewer players in the market. As such, discounts for biosimilar products have not been as steep as traditional generics. As a greater number of players enter the market and additional products are approved we will see greater competition, which will lead to greater access to needed treatments, positively impacting the lives patients – the ultimate goal.”
The full interview can be found on www.biosimilars-northamerica.com/prcom.
Patrick will present a special keynote address giving an overview of the biosimilars market, including the key milsestones and hurdles the industry has overcome. He will also share some top tips on what to keep in mind moving forward.
He joins a speaker line-up comprised of experts shaping up the biosimilars landscape in North America including representatives from Sandoz, Harvest Moon Pharmaceuticals, Momenta, FUJIFILM Diosynth, Oncobiologics, Adelio, Covance, Zuckerman & Spaeder and more.
The full roster of speakers and their topics can be found on www.biosimilars-northamerica.com/prcom.
SMi’s Biosimilars North America conference will explore significant developmental topics within the sector including the impact of FDA’s newly implemented biosimilar interchangeability guidelines, the US market access landscape, and biosimilars of orphan drugs.
Registration is now live on the event website and there For more information visit www.biosimilars-northamerica.com/prcom.
4th Biosimilars North America
November 15 & 16, 2017
Renaissance Woodbridge Hotel, Iselin, NJ, USA
For delegate registration enquiries, contact Fateja Begum on fbegum@smi-online.co.uk. For media enquiries, contact Honey de Gracia at hdegracia@smi-online.co.uk.
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
In the run-up to the conference, SMi Group had a quickfire interview with Patrick Lucy. Patrick will be presenting an exclusive session at the conference on where the market for biosimilars is heading, including key milestones and challenges overcome.
Asked about the level of biosimilar discounting is optimal and will we ever see price matching between branded and biosimilar products, Patrick said, "Biosimilars are much more complex, requiring more resources and time to develop than small molecule drugs. In addition, there are far fewer players in the market. As such, discounts for biosimilar products have not been as steep as traditional generics. As a greater number of players enter the market and additional products are approved we will see greater competition, which will lead to greater access to needed treatments, positively impacting the lives patients – the ultimate goal.”
The full interview can be found on www.biosimilars-northamerica.com/prcom.
Patrick will present a special keynote address giving an overview of the biosimilars market, including the key milsestones and hurdles the industry has overcome. He will also share some top tips on what to keep in mind moving forward.
He joins a speaker line-up comprised of experts shaping up the biosimilars landscape in North America including representatives from Sandoz, Harvest Moon Pharmaceuticals, Momenta, FUJIFILM Diosynth, Oncobiologics, Adelio, Covance, Zuckerman & Spaeder and more.
The full roster of speakers and their topics can be found on www.biosimilars-northamerica.com/prcom.
SMi’s Biosimilars North America conference will explore significant developmental topics within the sector including the impact of FDA’s newly implemented biosimilar interchangeability guidelines, the US market access landscape, and biosimilars of orphan drugs.
Registration is now live on the event website and there For more information visit www.biosimilars-northamerica.com/prcom.
4th Biosimilars North America
November 15 & 16, 2017
Renaissance Woodbridge Hotel, Iselin, NJ, USA
For delegate registration enquiries, contact Fateja Begum on fbegum@smi-online.co.uk. For media enquiries, contact Honey de Gracia at hdegracia@smi-online.co.uk.
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Contact
SMi Group
Honey de Gracia
+44 (0) 20 7827 6048
http://www.biosimilars-northamerica.com/prcom
Honey de Gracia
+44 (0) 20 7827 6048
http://www.biosimilars-northamerica.com/prcom
Contact
Categories